

Prostate Cancer CME Series: Treatment Across the Prostate Cancer Continuum - Clinical Case Scenarios for Specialists

Stanford University School of Medicine

References

Boreta, L., Gadzinski, A. J., Wu, S. Y., Xu, M., Greene, K., Quanstrom, K., Nguyen, H. G., Carroll, P. R., Hope, T. A., & Feng, F. Y. (2019). Location of Recurrence by Gallium-68 PSMA-11 PET Scan in Prostate Cancer Patients Eligible for Salvage Radiotherapy. *Urology*, 129, 165-171. <https://doi.org/10.1016/j.urology.2018.12.055>

Carrie, C., Magné, N., Burban-Provost, P., Sargos, P., Latorzeff, I., Lagrange, J. L., Supiot, S., Belkacemi, Y., Peiffert, D., Allouache, N., Dubray, B. M., Servagi-Vernat, S., Suchaud, J. P., Crehange, G., Guerif, S., Brihoum, M., Barbier, N., Graff-Cailleaud, P., Ruffion, A., Dussart, S., ...Chabaud, S. (2019). Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial. *The Lancet. Oncology*, 20(12), 1740–1749. [https://doi.org/10.1016/S1470-2045\(19\)30486-3](https://doi.org/10.1016/S1470-2045(19)30486-3).

ECOG-ACRIN Cancer Research Group. *EA8183 / ERADICATE Educational Materials*. Accessed September 28, 2022. <https://ecog-acrin.org/clinical-trials/ea8183-educational-materials/>.

Hofman, M. S., Lawrentschuk, N., Francis, R. J., Tang, C., Vela, I., Thomas, P., Rutherford, N., Martin, J. M., Frydenberg, M., Shakher, R., Wong, L. M., Taubman, K., Ting Lee, S., Hsiao, E., Roach, P., Nottage, M., Kirkwood, I., Hayne, D., Link, E., . . . Murphy, D. G. (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): a prospective, randomised, multicentre study. *The Lancet*, 395(10231), 1208–1216. [https://doi.org/10.1016/s0140-6736\(20\)30314-7](https://doi.org/10.1016/s0140-6736(20)30314-7).

Morgans, A. K., Chen, Y.-H., Ferrari, A. C., Tran, P. T., Schaeffer, E. M., Shevrin, D. H., Szmulewitz, R. Z., Boike, T., Dorff, T. B., Liu, G., Wagner, L. I., Carducci, M. A. (2022). A phase III double blinded study of early intervention after radical prostatectomy with androgen deprivation therapy with darolutamide versus placebo in men at highest risk of prostate cancer metastasis by genomic stratification (eradicate). *Journal of Clinical Oncology*, 40(16_suppl). https://doi.org/10.1200/jco.2022.40.16_suppl.tps5114.

Perera, M., Papa, N., Christidis, D., Wetherell, D., Hofman, M. S., Murphy, D. G., Bolton, D., Lawrentschuk, N. (2016). Sensitivity, Specificity, and Predictors of Positive 68Ga-Prostate-specific Membrane Antigen Positron Emission Tomography in Advanced Prostate Cancer: A Systematic Review and Meta-analysis. *European urology*, 70(6), 926–937. <https://doi.org/10.1016/j.eururo.2016.06.021>.

Pollack, A., Karrison, T. G., Balogh, A. G., Gomella, L. G., Low, D. A., Bruner, D. W., Wefel, J. S., Martin, A. G., Michalski, J. M., Angyalfi, S. J., Lukka, H., Faria, S. L., Rodrigues, G. B., Beauchemin, M. C., Lee, R. J., Seaward, S. A., Allen, A. M., Monitto, D. C., Seiferheld, W., . . . Sandler, H. M. (2022). The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. *The Lancet*, 399(10338), 1886–1901. [https://doi.org/10.1016/s0140-6736\(21\)01790-6](https://doi.org/10.1016/s0140-6736(21)01790-6).

SWOG Cancer Research Network. *S1802: Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer*. Accessed September 28, 2022. <https://www.swog.org/clinical-trials/s1802>.

SWOG Cancer Research Network. *S1802 Protocol Video*. Accessed September 28, 2022. <https://www.swog.org/s1802-protocol-video>.

Shipley, W.U., Seiferheld, W., Lukka, H.R., Major, P.P., Heney, N.M., Grignon, D.J., Sartor, O., Patel, M.P., Bahary, J-P., et al. (2017). Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer. *New England Journal of Medicine*, 376:417-428. DOI: 10.1056/NEJMoa1607529.

Shipley, W. U., Pugh, S. L., Lukka, H. R., Major, P., Heney, N. M., Grignon, D. A., Sartor, O., Patel, M., Bahary, J.-P., Zietman, A. L., Pisansky, T. M., Zeitzer, K. L., Lawton, C. A., Feng, F. Y.-C., Lovett, R. D., Balogh, A. G., Souhami, L., Rosenthal, S. A., Kerlin, K., Sandler, H. M. (2016). NRG Oncology/RTOG 9601, a phase III trial in Prostate cancer patients: Anti-androgen therapy (AAT) with bicalutamide during and after salvage radiation therapy (RT) following radical prostatectomy (RP) and an elevated PSA. *Journal of Clinical Oncology*, 34(2_suppl), 3-3. https://doi.org/10.1200/jco.2016.34.2_suppl.3.

Smith, M. R., Hussain, M., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Kopyltsov, E., Park, C. H., Alekseev, B., Montesa-Pino, L., Ye, D., Parnis, F., Cruz, F., Tammela, T. L., Suzuki, H., Utriainen, T., Fu, C., Uemura, M., Méndez-Vidal, M. J., . . . Tombal, B. (2022). Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer. *New England Journal of Medicine*, 386(12), 1132–1142. <https://doi.org/10.1056/nejmoa2119115>.

Chapin, B., Southwest Oncology Group. (2018, Sept – 2031, Oct). *Phase III Randomized Trial of Standard Systemic Therapy (SST) Versus Standard Systemic Therapy Plus Definitive Treatment (Surgery or Radiation) of the Primary Tumor in Metastatic Prostate Cancer*. Identifier NCT03678025. <https://clinicaltrials.gov/ct2/show/NCT03678025>.

Fendler, W., Ferdinandus, J., Calais, J., Eiber, M., Flavell, R. R., Mishoe, A., Feng, F. Y., Nguyen, H. G., Reiter, R. E., Rettig, M., Gartmann, J., Smith, R., Small, E. J., Slavik, R., Carroll, P., Herrmann, K., Czernin, J., & Hope, T. (2020). Impact of 68Ga-PSMA-11 PET on the management of biochemically recurrent prostate cancer in a prospective single-arm clinical trial. *Journal of Clinical Oncology*, 38(6_suppl), 292–292. https://doi.org/10.1200/jco.2020.38.6_suppl.292.

Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., Tombal, B., Supiot, S., Berthold, D., Ronchin, P., Kacso, G., Gravis, G., Calabro, F., Berdahl, J. F., Hasbini, A., Silva, M., Thiery-Vuillemin, A., Latorzeff, I., Mourey, L., . . . Bossi, A. (2022). Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. *The Lancet*, 399(10336), 1695–1707. [https://doi.org/10.1016/s0140-6736\(22\)00367-1](https://doi.org/10.1016/s0140-6736(22)00367-1).